Explore Onyx Biotec IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Founded in 2005, Onyx Biotec Limited is a prominent player in the pharmaceutical sector, specializing in the production of sterile pharmaceutical products such as Sterile Water for Injections, Dry Powder Injections, and Dry Syrup. Onyx serves major pharmaceutical companies across India and internationally. The company operates two WHO-GMP certified manufacturing facilities in Himachal Pradesh, focused on stringent quality control, sustainable practices, and modern production processes. Onyx also provides contract manufacturing services and regulatory dossier preparation, leveraging advanced equipment to meet global standards. The company is undertaking strategic upgrades, including expanding capacity for intravenous products and implementing high-speed packaging lines to enhance efficiency and product safety.
Key Points:
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
Fields | Details |
---|---|
IPO Dates | 13 Nov - 18 Nov 2024 |
IPO Price Band | ₹58 - ₹61 per share |
Fresh Issue | 48,10,000 shares |
Offer For Sale | NIL |
Total IPO Size | ₹29.34 crore |
Face Value | ₹10 |
Listing On | NSE |
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
Event | Date |
---|---|
IPO Opening Date | 13 Nov 2024 |
IPO Closing Date | 18 Nov 2024 |
Basis Of Allotment | 19 Nov 2024 |
Refunds | 20 Nov 2024 |
Demat Transfer | 20 Nov 2024 |
IPO Listing Date | 21 Nov 2024 |
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | May 2024 |
---|---|---|---|---|
Total Income | 44.98 | 39.62 | 53.87 | 10.54 |
Total Expenses | 41.19 | 37.07 | 49.82 | 8.79 |
Net Profit/Loss | 3.35 | 1.84 | 3.03 | 1.31 |
NPM (*) | 7.47 | 4.67 | 5.64 | 12.42 |
Total Assets | 36.84 | 58.72 | 74.14 | 74.77 |
Total Liabilities | 20.46 | 40.52 | 49.26 | 48.58 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
Period Ended | 31st March 2022 | 31st March 2023 | 31st March 2024 | May 2024 |
---|---|---|---|---|
EPS | 2.84 | 1.56 | 2.54 | 0.98 |
ROE (%) | 14.35 | 6.29 | 10.58 | 3.71 |
ROCE (%) | 20.47 | 10.13 | 12.19 | 4.99 |
D/E Ratio | 0.75 | 1.61 | 1.24 | 1.21 |
Current Ratio | 1.44 | 0.72 | 1.31 | 1.38 |
EBITDA MARGIN (%) | 12.57 | 11.31 | 15.41 | 26.01 |
* Compiled from DRHP/RHP for valuation purposes.
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
Name | Revenue | P/E | EPS | RoNW | NAV |
---|---|---|---|---|---|
Onyx Biotec Limited | 53.75 | 26.75 | 2.28 | 12.19 | 18.67 |
Suven Pharma | 1,051.35 | 83.92 | 11.80 | 14.64 | 375.82 |
JB Chemicals | 3,484.18 | 53.63 | 35.66 | 18.90 | 188.37 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
Investor Type | Shares Offered |
---|---|
Qualified Institutional Buyer (QIB) | Not more than 49.89% |
Non-Institutional Investor (NII/HNI) | Not less than 15.07% |
Retail Individual Investor (RII) | Not less than 35.04% |
Investor Type | Subscribed |
---|---|
Qualified Institutional Buyer (QIB) | 32.49 |
Non-Institutional Investor (NII/HNI) | 602.86 |
Retail Individual Investor (RII) | 118.26 |
Total | 198 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
MAS Services Limited
Phone: +91 112 638 7281/83, 114 132 0335
Email: ipo@masserv.com
Website: www.masserv.com
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar, Nalagarh Road, District Solan – 174 101, Himachal Pradesh, India.
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: www.onyxbiotec.com